首页> 外文期刊>Neuropathology: official journal of the Japanese Society of Neuropathology >Prognostic significance of the immunohistochemical expression of O6-methylguanine-DNA methyltransferase, P-glycoprotein, and multidrug resistance protein-1 in glioblastomas.
【24h】

Prognostic significance of the immunohistochemical expression of O6-methylguanine-DNA methyltransferase, P-glycoprotein, and multidrug resistance protein-1 in glioblastomas.

机译:胶质母细胞瘤中O6-甲基鸟嘌呤-DNA甲基转移酶,P-糖蛋白和多药耐药蛋白-1的免疫组织化学表达的预后意义。

获取原文
获取原文并翻译 | 示例
           

摘要

We studied the expression of O(6)-methylguanine-DNA methyltransferase (O(6)-MGMT), P-glycoprotein (Pgp), and multidrug resistance protein-1 (MRP-1) in 23 glioblastomas using RT-PCR, methylation-specific PCR, and immunohistochemistry, and analyzed their association with overall patient survival. Univariate analysis of collected data demonstrated that the expressions of O(6)-MGMT and MRP-1 detected by immunohistochemistry, in addition to the consistent factors, including preoperative Karnofsky performance scale (KPS), radical surgery, and tumor location and extension, were significant prognostic factors for the overall survival (OS) of patients with glioblastoma, who received nimustine (ACNU)-based chemotherapy in association with surgery and radiotherapy. Among them, following multivariate analysis, preoperative KPS, radical surgery, tumor location, and the expression of O(6)-MGMT remained as significant prognostic factors. These findings suggest that immunohistochemical analysis of O(6)-MGMT in patients with glioblastoma can be a useful method to predict the effects of chemotherapy and identify alternative chemotherapeutic regimens for O(6)-MGMT-positive patients.
机译:我们使用RT-PCR,甲基化研究了23种胶质母细胞瘤中O(6)-甲基鸟嘌呤-DNA甲基转移酶(O(6)-MGMT),P-糖蛋白(Pgp)和多药耐药蛋白1(MRP-1)的表达特异性PCR和免疫组织化学,并分析了它们与患者总体存活率的关系。对收集到的数据进行单因素分析表明,除包括手术前卡氏表现量表(KPS),根治性手术以及肿瘤的位置和范围在内的一致因素外,通过免疫组织化学检测到的O(6)-MGMT和MRP-1的表达是胶质母细胞瘤患者的总体生存(OS)的重要预后因素,这些患者接受了以尼莫斯汀(ACNU)为基础的化学疗法以及手术和放疗。其中,经过多变量分析,术前KPS,根治性手术,肿瘤位置和O(6)-MGMT的表达仍然是重要的预后因素。这些发现表明,胶质母细胞瘤患者O(6)-MGMT的免疫组织化学分析可能是预测化学作用和确定O(6)-MGMT阳性患者替代化疗方案的有用方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号